This is a match-making section for JPIAMR 17th call - AMR Interventions 2024 (IMPACT).
Human Health
Candida drug resistance mechanisms evolution genome scale metabolic models drug target identification
The FunPath Lab, which I lead, is focused on understanding fungal infections caused by pathogenic yeasts of the Candida genus, on a genome-wide perspective, and on using this information to improve therapeutic options. My lab has 15 years of experience on characterizing new mechanisms of drug resistance in Candida, especially focused on transporters and transcription factor. We have also keen interest on understanding the genomic evolution of drug resistance acquisition, and using genome-scale models to identify promising new drug targets.
Projects aiming to better characterize the molecular basis underlying the acquisition of drug resistance in fungal pathogens, to identify novel drug targets and novel drugs.
Submitted on 2024-02-16 12:08:31
« Return to the partner search tool